IL109016A - Purified soluble vascular endothelial cell growth factor (vegf) inhibitor encoding purified dna, a process for its preparation and pharmaceutical compositions comprising it - Google Patents
Purified soluble vascular endothelial cell growth factor (vegf) inhibitor encoding purified dna, a process for its preparation and pharmaceutical compositions comprising itInfo
- Publication number
- IL109016A IL109016A IL10901694A IL10901694A IL109016A IL 109016 A IL109016 A IL 109016A IL 10901694 A IL10901694 A IL 10901694A IL 10901694 A IL10901694 A IL 10901694A IL 109016 A IL109016 A IL 109016A
- Authority
- IL
- Israel
- Prior art keywords
- vegf
- growth factor
- cell growth
- vascular endothelial
- endothelial cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3876993A | 1993-03-25 | 1993-03-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL109016A0 IL109016A0 (en) | 1994-06-24 |
IL109016A true IL109016A (en) | 2005-07-25 |
Family
ID=21901791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10901694A IL109016A (en) | 1993-03-25 | 1994-03-17 | Purified soluble vascular endothelial cell growth factor (vegf) inhibitor encoding purified dna, a process for its preparation and pharmaceutical compositions comprising it |
Country Status (12)
Country | Link |
---|---|
US (5) | US5712380A (xx) |
EP (1) | EP0694042B1 (xx) |
JP (1) | JP3734262B2 (xx) |
AT (1) | ATE281469T1 (xx) |
AU (1) | AU684498B2 (xx) |
CA (1) | CA2158745C (xx) |
DE (1) | DE69434115T2 (xx) |
DK (1) | DK0694042T3 (xx) |
ES (1) | ES2230542T3 (xx) |
IL (1) | IL109016A (xx) |
PT (1) | PT694042E (xx) |
WO (1) | WO1994021679A1 (xx) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6710174B2 (en) * | 2001-09-13 | 2004-03-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of vascular endothelial growth factor receptor-1 expression |
GB9410534D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
GB9410533D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Vegf結合性ポリペプチド |
US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
GB9601640D0 (en) * | 1996-01-26 | 1996-03-27 | Cancer Res Campaign Tech | Ligand directed enzyme prodrug therapy |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
DE69733204T3 (de) | 1996-07-15 | 2012-03-08 | Chugai Seiyaku K.K. | Neuartige vegf-ähnliche faktoren |
JP2001501471A (ja) * | 1996-09-24 | 2001-02-06 | メルク エンド カンパニー インコーポレーテッド | 血管新生の阻害のための遺伝子治療 |
US6750044B1 (en) * | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
JP3837748B2 (ja) | 1997-01-17 | 2006-10-25 | 東亞合成株式会社 | Vegf結合性ポリペプチド |
EP1086705A4 (en) * | 1998-05-20 | 2002-02-06 | Kyowa Hakko Kogyo Kk | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTIVITY |
US6200954B1 (en) * | 1998-09-04 | 2001-03-13 | National University Of Singapore | Small peptides having potent anti-angiogenic activity |
US7317003B2 (en) * | 1998-09-04 | 2008-01-08 | National University Of Singapore | Small peptides having anti-angiogenic and endothelial cell inhibition activity |
US6696063B1 (en) * | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
CA2359461A1 (en) * | 1999-01-15 | 2000-07-20 | Medstar Research Institute | Inhibiting development of microvessels within vascular walls |
US7303746B2 (en) * | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
GB9928950D0 (en) * | 1999-12-07 | 2000-02-02 | Metris Therapeutics Limited | Binding protein |
US20030036524A1 (en) * | 2000-03-08 | 2003-02-20 | Jens Licthenberg | Method of sensitising endothelial cells to prodrugs |
EP1581615B1 (en) | 2000-09-05 | 2010-04-28 | Biosight Ltd | Peptide conjugated anti-cancer prodrugs |
US6734017B2 (en) | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
AU2003215163A1 (en) * | 2002-02-12 | 2003-09-04 | Vanderbilt University | Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy |
US20040101478A1 (en) * | 2002-03-29 | 2004-05-27 | Thomas Kenneth A | In vivo methods of determining activity of receptor-type kinase inhibitors |
CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
CN103073620B (zh) * | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
US7432341B2 (en) * | 2002-10-24 | 2008-10-07 | Valo Hsj, Limited Partnership | Cytokine receptor modulators and method of modulating cytokine receptor activity |
US20040266688A1 (en) * | 2003-05-14 | 2004-12-30 | Nayak Nihar R | Methods for modulating endometrium |
AU2004265226A1 (en) * | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Intron fusion proteins, and methods of identifying and using same |
US7186699B2 (en) * | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
WO2005069906A2 (en) * | 2004-01-16 | 2005-08-04 | Yale University | Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases |
US8618054B2 (en) * | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
WO2005113596A2 (en) * | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
JP4680997B2 (ja) * | 2004-06-08 | 2011-05-11 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管新生を阻害するキメラタンパク質およびその利用 |
US20080171033A1 (en) * | 2004-08-26 | 2008-07-17 | Chiwen Chang | Compositions and methods for treating diseases associated with angiogenesis and inflammation |
EP1804835B9 (en) | 2004-09-13 | 2010-09-29 | Genzyme Corporation | Multimeric constructs |
US8841259B2 (en) * | 2005-02-24 | 2014-09-23 | Joslin Diabetes Center | Compositions and methods for treating vascular permeability |
EP2289533B1 (en) | 2005-02-28 | 2013-09-18 | Oncotherapy Science, Inc. | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
US20090170769A1 (en) * | 2005-05-13 | 2009-07-02 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
WO2007009071A2 (en) * | 2005-07-13 | 2007-01-18 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating an inflammatory response |
US9198981B2 (en) * | 2006-02-01 | 2015-12-01 | The University Of Kentucky | Modulation of angiogenesis |
US20100119512A1 (en) * | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
TWI436775B (zh) | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
RU2010133157A (ru) | 2008-01-07 | 2012-02-20 | Орто-Клиникал Дайэгностикс, Инк. (Us) | Определение комплекса sflt-1:ангиогенный фактор |
WO2009149205A2 (en) * | 2008-06-03 | 2009-12-10 | Neurotech Usa, Inc. | Cell lines that secrete soluble vegf receptors and uses thereof |
WO2010091234A2 (en) | 2009-02-06 | 2010-08-12 | The General Hospital Corporation | Methods of treating vascular lesions |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
TW201109029A (en) | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
ES2354922B1 (es) | 2009-09-02 | 2012-02-07 | Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron | Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer. |
WO2011028642A1 (en) | 2009-09-04 | 2011-03-10 | University Of Louisville Research Foundation, Inc. | Genetic determinants of prostate cancer risk |
SI2601214T1 (en) | 2010-08-06 | 2018-03-30 | Genzyme Corporation | VEGF antagonist compositions and their use |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
TWI702955B (zh) | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
AU2014205369B2 (en) | 2013-01-11 | 2018-08-09 | Massachusetts Eye And Ear Infirmary | CYP450 lipid metabolites reduce inflammation and angiogenesis |
EP2994758B1 (en) | 2013-05-08 | 2017-12-20 | Opthea Limited | Biomarkers for age-related macular degeneration (amd) |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
AU2015231439B2 (en) | 2014-03-17 | 2019-11-14 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
KR101819135B1 (ko) | 2014-03-18 | 2018-01-18 | 한국과학기술원 | 당화 vegf 디코이 수용체 융합 단백질 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3170005B1 (en) | 2014-07-18 | 2019-04-10 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
AU2017257169B2 (en) | 2016-04-29 | 2021-07-08 | Adverum Biotechnologies, Inc. | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
WO2017218981A2 (en) | 2016-06-16 | 2017-12-21 | Adverum Biotechnologies, Inc. | Compositions and methods for reducing ocular neovascularization |
CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018170473A1 (en) | 2017-03-17 | 2018-09-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
WO2019147944A1 (en) | 2018-01-26 | 2019-08-01 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disordres using anti-vegf agents |
JP7384815B2 (ja) * | 2018-03-22 | 2023-11-21 | ザ チルドレンズ メディカル センター コーポレーション | 肺の修復に関する方法および組成物 |
TW202106699A (zh) | 2019-04-26 | 2021-02-16 | 美商愛德維仁生物科技公司 | 用於玻璃體內遞送之變異體aav蛋白殼 |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
JP2024519888A (ja) | 2021-05-28 | 2024-05-21 | 上海瑞宏迪医薬有限公司 | カプシド変異を有する組換えアデノ随伴ウイルス及びその応用 |
CA3233983A1 (en) * | 2021-11-02 | 2023-05-11 | Ole-Jan Iversen (Deceased) | Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG49753A1 (en) * | 1991-02-22 | 1998-06-15 | American Cyanamid Co | Identification of a novel human receptor tyrosine kinase gene |
DE69233739D1 (de) * | 1992-10-28 | 2008-08-07 | Genentech Inc | Verwendung von Antagonisten des Zellwachstumsfaktors VEGF |
CN1701814A (zh) * | 1992-11-13 | 2005-11-30 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
-
1994
- 1994-02-25 CA CA002158745A patent/CA2158745C/en not_active Expired - Fee Related
- 1994-02-25 DK DK94911403T patent/DK0694042T3/da active
- 1994-02-25 AT AT94911403T patent/ATE281469T1/de not_active IP Right Cessation
- 1994-02-25 ES ES94911403T patent/ES2230542T3/es not_active Expired - Lifetime
- 1994-02-25 AU AU63934/94A patent/AU684498B2/en not_active Ceased
- 1994-02-25 PT PT94911403T patent/PT694042E/pt unknown
- 1994-02-25 WO PCT/US1994/001957 patent/WO1994021679A1/en active IP Right Grant
- 1994-02-25 DE DE69434115T patent/DE69434115T2/de not_active Expired - Fee Related
- 1994-02-25 JP JP52104194A patent/JP3734262B2/ja not_active Expired - Fee Related
- 1994-02-25 EP EP94911403A patent/EP0694042B1/en not_active Expired - Lifetime
- 1994-03-17 IL IL10901694A patent/IL109016A/xx active IP Right Grant
- 1994-04-21 US US08/232,538 patent/US5712380A/en not_active Expired - Lifetime
-
1997
- 1997-01-21 US US08/786,164 patent/US5861484A/en not_active Expired - Lifetime
-
2002
- 2002-03-19 US US10/101,018 patent/US7071159B2/en not_active Expired - Fee Related
-
2006
- 2006-03-14 US US11/375,523 patent/US20070010442A1/en not_active Abandoned
-
2009
- 2009-02-06 US US12/322,800 patent/US8034772B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH08508161A (ja) | 1996-09-03 |
US7071159B2 (en) | 2006-07-04 |
US5861484A (en) | 1999-01-19 |
JP3734262B2 (ja) | 2006-01-11 |
CA2158745A1 (en) | 1994-09-29 |
EP0694042A4 (en) | 2001-05-02 |
EP0694042A1 (en) | 1996-01-31 |
AU684498B2 (en) | 1997-12-18 |
US5712380A (en) | 1998-01-27 |
WO1994021679A1 (en) | 1994-09-29 |
PT694042E (pt) | 2005-02-28 |
US20030120038A1 (en) | 2003-06-26 |
US8034772B2 (en) | 2011-10-11 |
DE69434115D1 (de) | 2004-12-09 |
ATE281469T1 (de) | 2004-11-15 |
EP0694042B1 (en) | 2004-11-03 |
DK0694042T3 (da) | 2005-02-14 |
US20090247460A1 (en) | 2009-10-01 |
AU6393494A (en) | 1994-10-11 |
CA2158745C (en) | 2007-06-19 |
DE69434115T2 (de) | 2005-10-27 |
ES2230542T3 (es) | 2005-05-01 |
IL109016A0 (en) | 1994-06-24 |
US20070010442A1 (en) | 2007-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL109016A (en) | Purified soluble vascular endothelial cell growth factor (vegf) inhibitor encoding purified dna, a process for its preparation and pharmaceutical compositions comprising it | |
IL130492A0 (en) | Ligand for receptor activator of NF-Kappa B | |
WO2001062942A3 (en) | MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS | |
ES2187946T3 (es) | Uso de interleucina-15. | |
WO1996006108A3 (en) | Cyclic cs-1 peptidomimetics, compositions and methods of using the same | |
IL142905A0 (en) | Functional antagonists of hedgehog activity | |
HK1001464A1 (en) | Receptor on the surface of activated t-cells:acts-4 | |
NZ504114A (en) | Vitamin k-dependent polypeptides such as protein C where substitution at amino acid sites 11, 12, 29, 33 or 34 affects membrane binding affinity of the protein and ultimately blood clotting ability | |
AU4162400A (en) | Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii | |
PT931092E (pt) | Variantes de factor de crescimento de celulas endoteliais vasculares que possuem propriedades antagonistas | |
DK1175909T3 (da) | Terapeutiske sammensætninger af antistoffer og antisense-nukleinsyrer mod Serrate | |
EP1967590A3 (en) | Lentiviral packaging constructs | |
Palaszynski | Synthetic C-terminal peptide of IL-1 functions as a binding domain as well as an antagonist for the IL-1 receptor | |
NZ514488A (en) | Vascular endothelial cell growth factor variants and uses thereof | |
CA2200980A1 (en) | Mammalian receptors for modified low-density lipoprotein | |
NO982715D0 (no) | Endotel celle-proliferasjonsinhibitor og fremgangsmÕte for anvendelse | |
BG105761A (en) | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | |
PT1137413E (pt) | Antagonistas nao-peptidicos do receptor de glp-1 e metodos de utilizacao | |
ES2153433T3 (es) | Inhibidores de trombina bivalentes. | |
WO1995027060A3 (en) | Biologically active eph family ligands | |
AU6435700A (en) | Cyclic peptidomimetic urokinase receptor antagonists | |
AU7525398A (en) | Inhibitors for urokinase receptor | |
WO1996023884A3 (en) | Human peroxisome proliferator activated receptors | |
AP9801182A0 (en) | Endothelin receptor antagonists. | |
WO1995016036A3 (en) | IFN-ηRECEPTOR β-CHAIN AND DERIVATIVES THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |